Propanc Biopharma shares surge 14.16% premarket after announcing strategic acquisition of undervalued Digital Asset Treasury companies holding Bitcoin and Ethereum.

Propanc Biopharma (PPCB) surged 14.16% in premarket trading following the announcement of a strategic acquisition plan targeting Digital Asset Treasury (DAT) companies trading below their Market Cap to Net Asset Value (MNAV). The company highlighted opportunities to acquire undervalued DAT entities holding substantial reserves of Bitcoin and Ethereum, with Bitcoin Treasury companies collectively valued at $76.9 billion and Ethereum-based DATs at $17.6 billion. CEO James Nathanielsz emphasized the initiative as a diversification strategy to strengthen Propanc’s balance sheet, create shareholder value, and leverage its public company platform. The press release noted that many DATs trade at significant discounts to their net asset values, positioning the move as a capital-efficient opportunity to build a digital asset portfolio alongside its oncology pipeline. Multiple news events reiterated the same strategic focus, reinforcing the bullish sentiment driving the stock’s premarket rally.